| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | 0.29 | 1e-12 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.34 | 5e-12 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.26 | 6e-10 |
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | 0.24 | 9e-10 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.23 | 2e-09 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | 0.28 | 3e-09 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.28 | 4e-09 |
| mRNA | HG-6-64-1 | GDSC1000 | pan-cancer | AAC | 0.28 | 9e-09 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | 0.24 | 1e-08 |
| mRNA | I-BET-762 | GDSC1000 | pan-cancer | AAC | 0.22 | 2e-08 |